155 related articles for article (PubMed ID: 24568891)
21. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
22. Concizumab: First Approval.
Keam SJ
Drugs; 2023 Jul; 83(11):1053-1059. PubMed ID: 37341887
[TBL] [Abstract][Full Text] [Related]
23. Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086.
Parng C; Singh P; Pittman DD; Wright K; Leary B; Patel-Hett S; Rakhe S; Stejskal J; Peraza M; Dufield D; Murphy JE; Webster R
J Pharm Sci; 2018 Jul; 107(7):1995-2004. PubMed ID: 29571739
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.
Bihorel S; Fiedler-Kelly J; Ludwig E; Sloan-Lancaster J; Raddad E
AAPS J; 2014 Sep; 16(5):1009-17. PubMed ID: 24912797
[TBL] [Abstract][Full Text] [Related]
25. The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats.
Dahlberg AM; Kaminskas LM; Smith A; Nicolazzo JA; Porter CJ; Bulitta JB; McIntosh MP
Mol Pharm; 2014 Feb; 11(2):496-504. PubMed ID: 24350780
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice.
Wu F; Tamhane M; Morris ME
AAPS J; 2012 Jun; 14(2):252-61. PubMed ID: 22391791
[TBL] [Abstract][Full Text] [Related]
27. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
[TBL] [Abstract][Full Text] [Related]
28. Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives.
Pasca S
J Blood Med; 2022; 13():191-199. PubMed ID: 35465188
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
30. Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.
Komocsar WJ; Blackbourne JL; Halstead CA; Winstead CJ; Wierda D
J Immunotoxicol; 2016; 13(1):7-19. PubMed ID: 25585959
[TBL] [Abstract][Full Text] [Related]
31. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.
Shapiro AD; Angchaisuksiri P; Astermark J; Benson G; Castaman G; Chowdary P; Eichler H; Jiménez-Yuste V; Kavakli K; Matsushita T; Poulsen LH; Wheeler AP; Young G; Zupancic-Salek S; Oldenburg J
Blood; 2019 Nov; 134(22):1973-1982. PubMed ID: 31444162
[TBL] [Abstract][Full Text] [Related]
33. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
[TBL] [Abstract][Full Text] [Related]
34. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T; Shapiro A; Abraham A; Angchaisuksiri P; Castaman G; Cepo K; d'Oiron R; Frei-Jones M; Goh AS; Haaning J; Hald Jacobsen S; Mahlangu J; Mathias M; Nogami K; Skovgaard Rasmussen J; Stasyshyn O; Tran H; Vilchevska K; Villarreal Martinez L; Windyga J; You CW; Zozulya N; Zulfikar B; Jiménez-Yuste V;
N Engl J Med; 2023 Aug; 389(9):783-794. PubMed ID: 37646676
[TBL] [Abstract][Full Text] [Related]
35. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
36. A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
Le KN; Gibiansky L; Good J; Davancaze T; van Lookeren Campagne M; Loyet KM; Morimoto A; Jin J; Damico-Beyer LA; Hanley WD
J Pharmacol Exp Ther; 2015 Nov; 355(2):288-96. PubMed ID: 26359312
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
[TBL] [Abstract][Full Text] [Related]
38. Minimal interference of concizumab with standard clinical coagulation laboratory assays - An in vitro study.
Augustsson C; Strandberg K; Kjalke M
Haemophilia; 2024 Jun; ():. PubMed ID: 38924198
[TBL] [Abstract][Full Text] [Related]
39. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Nnane IP; Xu Z; Zhou H; Davis HM
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone.
Porchet HC; Le Cotonnec JY; Neuteboom B; Canali S; Zanolo G
J Clin Endocrinol Metab; 1995 Feb; 80(2):667-73. PubMed ID: 7852534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
